| |||||||||||||||
Sunday, June 30, 2013
Big Train Overcome Deficit; Health Night TONIGHT; BT Players in Pro Ball!
A cup of this a day keeps cancer away
Clobber Cancer with a Daily Cup of This...
If you like the idea of warding off cancer with a simple cup of tea, I've got good news. New evidence shows chamomile tea contains a super powerful chemical that not only blocks the spread of cancer, but also shortens the life of a cancer cell.
On top of that, chamomile can even make a cancer cell more susceptible to the effects of drug therapy, working in hand in hand with conventional treatment methods. Keep reading to find out how to easily incorporate this simple daily ritual into your cancer-fighting plan...
Continued below. . .
On top of that, chamomile can even make a cancer cell more susceptible to the effects of drug therapy, working in hand in hand with conventional treatment methods. Keep reading to find out how to easily incorporate this simple daily ritual into your cancer-fighting plan...
Continued below. . .
Foods You Should Never Mix
With These Popular Supplements!
Dear Nathan,
There's something that you should know about the vitamins you're taking. What you could be mixing with your vitamins might actually be making you sick. Because vitamins aren't as strictly regulated as pharmaceutical drugs, a lot of times the labels don't warn you that you could be taking a harmful dose of vitamins simply by mixing them with other vitamins and nutrients found in every day foods. My name is Dr. David Juan and I've been a practicing medical doctor for over 30 years. When it comes to the dangerous interactions of foods, drugs and vitamins, I've got the qualifications to back up what I'm talking about. That's why they call me The Vitamin Doctor. And I want to warn you about the constant dangers resulting from vitamin, food and drug interactions that have already harmed others. To see the dangerous and hidden pitfalls of today's most popular supplements, watch this now. |
The re-education of cancer cells
The magic ingredient at work in chamomile tea is a chemical called apigenin. The apigenin compound is plentiful in the Mediterranean diet, which you may be familiar with. The compound is also commonly found in celery, parsley, and several other fruits and vegetables. Chamomile itself is a daisy-like flower, used often in German and Hungarian herbal remedies.
In a recent study by scientists at Ohio State University, published in the journalProceedings of the National Academy of Sciences, apigenins were found to be effective in teaching cancer cells "who's boss."
I mean that in the literal sense. Apigenins appear to play a role in gene regulation, essentially reprogramming cancer cells so they act more like normal cells and die on schedule. This is key, because one of the reasons cancer cells can so quickly take over is their ability to prevent apoptosis -- regularly-scheduled cell death.
Unlike healthy cells, which die off after a time, cancer cells are practically immortal. So in the worst cases, cancer cells grow stronger and accumulate over time.
But, with apigenins in the picture, it appears that cancer cells experience normal cell death.
In a recent study by scientists at Ohio State University, published in the journalProceedings of the National Academy of Sciences, apigenins were found to be effective in teaching cancer cells "who's boss."
I mean that in the literal sense. Apigenins appear to play a role in gene regulation, essentially reprogramming cancer cells so they act more like normal cells and die on schedule. This is key, because one of the reasons cancer cells can so quickly take over is their ability to prevent apoptosis -- regularly-scheduled cell death.
Unlike healthy cells, which die off after a time, cancer cells are practically immortal. So in the worst cases, cancer cells grow stronger and accumulate over time.
But, with apigenins in the picture, it appears that cancer cells experience normal cell death.
How chamomile switches from calming tea to killing machine
One of the most striking discoveries in this body of research is that apigenins could potentially stop the spread of breast cancer. The latest research suggests apigenin binds to one of three types of proteins, each with a specific function. One of those proteins is called hnRNPA2. In a healthy hnRNPA2 protein, only one type of "splicing" takes place.
But in cancer cells, two types of splicing take place. This abnormal splicing is a factor in about 80 percent of all cancers. Splicing is important because it prompts the production of mRNA, or messenger RNA, which then carries out instructions regarding gene activation.
When apigenin connects with the hnRNPA2 protein in breast cancer cells, it changes the protein from two splices back to a single-splice setup. And with splicing back to normal, cells are able to die on schedule—or, at the very least, they become more vulnerable to the effects of chemotherapy drugs.
The Ohio State researchers found that apigenin binds with at least 160 proteins in the human body. This is highly significant, given that most pharmaceutical-based drugs can only target one molecule. The theory now is that perhaps other "nutraceuticals" (nutrients with known health benefits) can also bind to and affect more than one protein at a time.
The fact that apigenins can have relationships with so many specific proteins may be why they're able to reestablish a normal lifecycle in cancer cells. And now that scientists have gotten such valuable findings from exploring the effect of a natural compound on cancer cell research, it's fair to say more exploratory research regarding nutraceuticals is on its way.
But in cancer cells, two types of splicing take place. This abnormal splicing is a factor in about 80 percent of all cancers. Splicing is important because it prompts the production of mRNA, or messenger RNA, which then carries out instructions regarding gene activation.
When apigenin connects with the hnRNPA2 protein in breast cancer cells, it changes the protein from two splices back to a single-splice setup. And with splicing back to normal, cells are able to die on schedule—or, at the very least, they become more vulnerable to the effects of chemotherapy drugs.
The Ohio State researchers found that apigenin binds with at least 160 proteins in the human body. This is highly significant, given that most pharmaceutical-based drugs can only target one molecule. The theory now is that perhaps other "nutraceuticals" (nutrients with known health benefits) can also bind to and affect more than one protein at a time.
The fact that apigenins can have relationships with so many specific proteins may be why they're able to reestablish a normal lifecycle in cancer cells. And now that scientists have gotten such valuable findings from exploring the effect of a natural compound on cancer cell research, it's fair to say more exploratory research regarding nutraceuticals is on its way.
The sooner you start, the greater the benefit
If you read a newsletter like this, you know it's smart to eat healthy foods -- but mainstream medicine hangs back because there's often not enough research on how specific nutrients affect us. That's starting to change, and that's the reason understanding the role of apigenin is so significant. In a world where conventional scientists hate to recommend a medicinal substance without understanding the specific way it acts in the body, research like this brings them a step closer to supporting nutritional solutions to disease.
What's more, apigenins' profound health effects aren't limited to cancer treatment. They also have known anti-inflammatory properties. Consumed on a regular basis, they can help combat other health issues like heart disease and high cholesterol.
I'd caution you not to wait till science proves everything. Drink chamomile daily over the long term to reap the most health benefits. I should mention that chamomile has a reputation for being a sleep aid, so you may want to drink it at night. Taken first thing in the morning, it might slow you down.
What's more, apigenins' profound health effects aren't limited to cancer treatment. They also have known anti-inflammatory properties. Consumed on a regular basis, they can help combat other health issues like heart disease and high cholesterol.
I'd caution you not to wait till science proves everything. Drink chamomile daily over the long term to reap the most health benefits. I should mention that chamomile has a reputation for being a sleep aid, so you may want to drink it at night. Taken first thing in the morning, it might slow you down.
Saturday, June 29, 2013
How the Amish beat cancer time and time again
From the desk of Lee Euler, Editor and Publisher
The Amish Cancer Secret
 
How to cure just about any cancer the Amish way
Is it possible to cure just about any cancer the Amish way? Is it true that many Amish people easily get rid of cancer in just three or four weeks? Are the Amish onto something BIG?
To find out, I interviewed Jakob and Fannie, a young Amish couple from southern Minnesota. Jakob and Fannie are just two out of roughly 800 Amish people each year who travel 2,000 miles by train to go to a little-known cancer clinic.
They told me an amazing, lifesaving tip that everyone should know. . .but almost nobody does.
Click here and I’ll share it with you, absolutely FREE.
Kindest regards,
 Frank Cousineau Cancer Patient Advocate |
Thursday, June 27, 2013
Big Train Drop Lightning Shortened Game 4-1
Big Train Drop Lightning Shortened Game 4-1
|
The Big Train entered Wednesday's road game riding a three-game win streak, and were looking to make it four straight against the DC Grays. Due to lightning delays and anticipated darkness, the game would last just seven innings. | Box Score
Zach Morris (Maryland) got the start for the Big Train, and gave up just four hits and a walk over five innings. However, Morris would give up four runs, including three in the first inning.
The Big Train would rally in the fifth to bring the score closer. After back-to-back hits by Tyler France (San Diego State) and Tim Yandel (Tulane),Ryne Willard (Tallahassee CC) would hit a groundball to score France and make the score 4-1.
Will Resnik (High Point) gave the Big Train two shutout innings out of the bullpen, keeping the team in the game. However, the offense failed to score a run in the final two innings, and the Big Train went on to lose 4-1.
Despite the loss, the Big Train still boast a 12-4 record, good for a 2.5-game lead over the second-place Southern Maryland Nationals. They'll look to build on that lead on Thursday, as they host the Nationals at Povich Field at 7:30 PM.
|
Don't let cancer kill your bank account
Treating Cancer Is FINANCIALLY Toxic!
The diagnosis is devastating... the treatments doctors recommend can be traumatic...
... and when the bills start rolling in—you quickly realize that the cost of curing cancer is just about as bad as the disease! Here's what cancer does to your bank account, and what you can do about it... Continued below...
A recent study1 indicates that cancer patients are three times more likely to declare bankruptcy than people without the disease.
According to a June 2013 study from the Hutchinson Institute for Cancer Outcomes Research in Washington, younger people with cancer were five times more likely to declare bankruptcy compared to older patients. Those odds are alarming when you consider that tough economic times have driven bankruptcies sky high for people who aren't dealing with a cancer diagnosis! Study co-author Karma Kreizenbeck says that while their paper shows how cancer causes patients to run up medical debts that can lead to bankruptcy, "it could also mean people have to take second jobs, end up with lower credit scores or have to make other decisions." If you're wondering about the numbers, consider this estimate from the National Cancer Institute (NCI)2 ... According to their research, cancer costs in 2010 reached a staggering $124 billion in the United States. And you can bet these numbers will continue their upward trend, with some estimates of cancer costs reaching at least $158 billion by 2020. If you're already emotionally and physically exhausted from dealing with disease, the last thing you need is the stress of worrying about how to pay for treatments. But that's the unfortunate reality for thousands of sick cancer patients. Let's take a look at some of the costs you can expect to face…
A surefire way to drain your bank account
Cancer.net, a website of cancer information from American Society of Clinical Oncology, breaks down some of the common costs associated with cancer. These include:
This is just a snapshot of some of the costs you may incur. But it should be more than enough to show that fighting cancer is truly a financial burden.
So is there any help available?
Some resources to help ease your burden...
Of course, some of the most effective treatments are natural foods and supplements that don't cost very much at all. I firmly believe, based on the people we've interviewed during the last eight years, that patients can beat cancer on their own at home or by working with an alternative doctor on an outpatient basis.
Particularly for late-stage cancer patients, I believe the conventional treatments are almost worthless and you're better off with alternatives. Don't waste your last dollar on the chemo treatment that's supposed to give you two more months (it probably won't). Try the kinds of things Bill Henderson recommends in How to Cure Almost Any Cancer at Home for $5.15 or Day, or that Ty Bollinger recommends in The 31-Day Home Cancer Cure. These are proven, validated cancer protocols that work for a lot of people. They don't work for 100 percent of patients — that's not realistic -- but I'm convinced they have a MUCH higher success rate for late-stage cancer than do conventional treatments. But if you're an early-stage cancer patient you may decide to roll the dice on conventional treatments, or maybe you want to combine conventional and alternative therapies. Or perhaps you have a family member with cancer who won't consider alternatives. In that case, you may need to brace yourself for a financial shock. In Issue #268, we covered a variety of resources that are available to people in the mainstream medical system and — sometimes — to patients undergoing alternative treatments. I suggest you take a look at that issue, and make sure you aren't missing any help that might available. There are many non-profit organizations that provide assistance with medications, lodging, transportation, cleaning and other services for cancer patients. And "Obamacare" -- the new federal law officially known as The Affordable Care Act -- is supposed to make healthcare more affordable and available to people diagnosed with cancer and other grave diseases. We'll see. My wish is that the half million cancer patients diagnosed each year find the financial, emotional and medical support they need! 
Footnotes:
1Ramsey, S. et al. 2013. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Affairs. Published online before print May 2013, doi: 10.1377/hlthaff.2012.1263. Available at
http://content.healthaffairs. 2National Cancer Institute. (2011, January 11). Cancer prevalence and cost of care projections. Retrieved from http://costprojections.cancer. 3Duke Medicine News and Communications. 2011, June 6. Medical bills force cancer patients to skimp on care andnecessities.DukeHealth.org website. Available online at http://www.dukehealth.org/
Addtional Resources:
American Cancer Society. 2012. Health insurance and financial assistance for the cancer patient. Available at
http://www.cancer.org/ healthinsuranceandfinancialass financial-assistance-options- American Cancer Society. 2011. The Affordable Care Act: How it helps people with cancer and their families. Available at http://www.cancer.org/acs/ Grens, K. 2011. Cancer costs highest for individually insured. Fox News. Available at http://www.foxbusiness.com/ Lacoma, T. 2013. The average cost of chemotherapy. Available on the eHow website at http://www.ehow.com/about_ National Cancer Institute. 2013. Coping with cancer: Financial, legal and insurance information. Available at http://www.cancer.gov/ | |
| Health Disclaimer: The information provided above is not intended as personal medical advice or instructions. You should not take any action affecting your health without consulting a qualified health professional. The authors and publishers of the information above are not doctors or health-caregivers. The authors and publishers believe the information to be accurate but its accuracy cannot be guaranteed. There is some risk associated with ANY cancer treatment, and the reader should not act on the information above unless he or she is willing to assume the full risk. |
Tuesday, June 25, 2013
Big Train Sweep Monday Doubleheader
| |||
| |||
Monday, June 24, 2013
Big Train Get Revenge, Best Braves 10-4
Big Train Get Revenge, Best Braves 10-4
|
The Big Train sought to avenge Saturday's loss on Sunday, as they played the Herndon Braves in the second half of a weekend home-and-home series.
Michael Boyle (Radford) got the start for the Big Train, and gave the team six shutout innings. Boyle gave up just two hits and a walk while striking out seven. | Box Score
The scoring would get going for the Big Train in the second inning. After the team loaded the bases with one out, Ricky Santiago (Florida Atlantic) hit an RBI single and Parker Guinn (Washington) followed with a sacrifice fly to put the Big Train up 2-0. An RBI groundout by Ryne Willard (Tallahassee CC) in the sixth broughtTim Yandel (Tulane) home for the second time and the lead extended to 3-0. Most of the Big Train lineup reached base during the seventh inning. The Big Train were able to plate four of those runners thanks to a wild pitch, a fielder's choice, and a passed ball to increase the lead to 7-0. After forcing a pitching change, the Big Train would add two more runs, after Ty France (San Diego St.) laced a single. That made the lead 9-0, but the Braves would rally in the bottom half of the inning, scoring four runs. However, the Big Train would add an insurance run in the ninth to cap the 10-4 victory. With the victory, the Big Train are the first team in the CRCBL to ten wins and hold a 2.5-game lead for first place in the standings. The Big Train will look to build on their 2.5-game lead on Monday, as they host the Vienna Riverdogs for a doubleheader at Povich Field. The games are scheduled for 5:00 PM and 7:30 PM, respectively, and it's Shirley Povich Bobblehead Night! Come out to Povich Field and receive a bobblehead of the stadium's namesake if you're one of the first 500 fans! |
The TRUTH about whole grains
Diana Keuilian
|
Sunday, June 23, 2013
Support Your Divas
-Let us at US Sports Network do our part too. 10% of all proceeds for all new members of GoPro Workouts will be donated to the D.C. Divas Travel fund between now and July 10, 2013. So as you are getting in shape for next season, you will also be lending a helping hand to the real first ladies of football! Click here to get your program and support your Divas!
Mainstream Medicine Getting a Clue?
Mainstream Medicine Discovers What
|
Video of the Week:
"Shocking Confessions of a Drug Company Insider"
In this exposé, a top executive of a major pharmaceutical company spills the naked truth about the drugs you and your family take... which drugs heal, and which ones KILL... what doctors turn to when they don't know the cure... what they do when they themselves or their loved ones are stricken with disease or illness... what life-saving resource they insist should be in every home. Watch this must-see video now because your life -- or the life of your loved ones -- may depend on it.
|
In their quest to beat cancer, heavy-hitters like Bristol-Myers Squibb and Merck & Co. are now focusing on experimental drugs that work with the human immune system (instead of against it, the way chemotherapy does). The results so far look very promising.
Money is at the heart of it, of course, and investors are closely watching the progress of these drug tests. There's a chance we're going to see real results from these pharmaceutical treatments, and soon.
At the very least, these new drugs may extend the length of time cancer patients stay in remission. And with luck they may add years to a patient's life — or even lead to an outright cure for some types of cancer. But research on that won't be available for another year.
Equally exciting is that the new approach hints at a way to keep metastatic cancer under control for long periods of time, as opposed to jumping from one chemo drug to another as a tumor develops resistance. It turns out you don't need a succession of different chemo drugs to chase after shape-shifting cancer cells. You just need a strong immune system—exactly what cancer advocates like myself, Bill Henderson and Ty Bollinger have been saying for years.
That's because immunotherapy drugs (or better yet, natural immune boosters) allow a patient's immune system to keep up with mutations in a tumor. Early results of the new drugs suggest that patients given as few as nine months to live could survive for several years.
These new therapies could potentially bring in billions of dollars for the pharmaceutical companies promoting them. Really, it's the first innovative method for attacking cancer in a decade that's come out of Big Pharma. So much research in recent years has gone toward treating uncontrolled cell growth and genetic processes that little progress was made for treating advanced tumors.
Money is at the heart of it, of course, and investors are closely watching the progress of these drug tests. There's a chance we're going to see real results from these pharmaceutical treatments, and soon.
At the very least, these new drugs may extend the length of time cancer patients stay in remission. And with luck they may add years to a patient's life — or even lead to an outright cure for some types of cancer. But research on that won't be available for another year.
Equally exciting is that the new approach hints at a way to keep metastatic cancer under control for long periods of time, as opposed to jumping from one chemo drug to another as a tumor develops resistance. It turns out you don't need a succession of different chemo drugs to chase after shape-shifting cancer cells. You just need a strong immune system—exactly what cancer advocates like myself, Bill Henderson and Ty Bollinger have been saying for years.
That's because immunotherapy drugs (or better yet, natural immune boosters) allow a patient's immune system to keep up with mutations in a tumor. Early results of the new drugs suggest that patients given as few as nine months to live could survive for several years.
These new therapies could potentially bring in billions of dollars for the pharmaceutical companies promoting them. Really, it's the first innovative method for attacking cancer in a decade that's come out of Big Pharma. So much research in recent years has gone toward treating uncontrolled cell growth and genetic processes that little progress was made for treating advanced tumors.
They see dollars, and lots of 'em. . .
Bristol-Myers is developing a new immune-boosting cancer drug candidate called nivolumab. If it works for lung cancer, as they hope, it could bring in sales close to the recent drug Avastin: $5.8 billion in sales just last year. Made by Roche, Avastin is used to fight colon cancer and other tumors.
The concept behind drugs that strengthen the immune system is this: The immune system is able to respond to changes in the body's enemies. Get the immune system to adapt to fighting any dangerous malignancy, and you'll give mutating cancer cells a fair fight. The immune cells are able to change right along with the cancer cells. The new immunotherapy drugs target the immune system's T-cells, well known as our body's key defenders against germs and infections.
T-cells have something akin to an off-switch, called PD-1. These new immune-boosting drugs essentially prevent this switch from ever going off. This makes it more likely for T-cells to recognize and attack invading tumors as dangerous. Prior to this, tumors were able to fly under the T-cell radar and weren't immediately recognized as a risk.
But—and this is the most important point of all—many experts feel this new revolution in drug design will bring about a paradigm shift for fighting cancer. That is to say, it's a paradigm shift for mainstream medicine. Alternative therapies have focused on the immune system for decades.
Merck's senior vice president Gary Gilliland stated immune therapy was the key to finally eradicating tumors. "We are pretty good at shrinking tumors," he said in an interview, "but not good at getting rid of them." This could be the key.
The concept behind drugs that strengthen the immune system is this: The immune system is able to respond to changes in the body's enemies. Get the immune system to adapt to fighting any dangerous malignancy, and you'll give mutating cancer cells a fair fight. The immune cells are able to change right along with the cancer cells. The new immunotherapy drugs target the immune system's T-cells, well known as our body's key defenders against germs and infections.
T-cells have something akin to an off-switch, called PD-1. These new immune-boosting drugs essentially prevent this switch from ever going off. This makes it more likely for T-cells to recognize and attack invading tumors as dangerous. Prior to this, tumors were able to fly under the T-cell radar and weren't immediately recognized as a risk.
But—and this is the most important point of all—many experts feel this new revolution in drug design will bring about a paradigm shift for fighting cancer. That is to say, it's a paradigm shift for mainstream medicine. Alternative therapies have focused on the immune system for decades.
Merck's senior vice president Gary Gilliland stated immune therapy was the key to finally eradicating tumors. "We are pretty good at shrinking tumors," he said in an interview, "but not good at getting rid of them." This could be the key.
The results are astounding
Bristol-Myers did something similar two years ago with a drug called Yervoy, tested on patients suffering from advanced, late-stage melanoma. Melanoma is the deadliest form of skin cancer, and indeed one of the deadliest of all cancers.
Yervoy doubled the number of patients surviving four years after their diagnosis to 19 percent. This success is what brought the idea of immunotherapy to light in conventional care. Now you might say immunotherapy has officially been accepted into mainstream medicine.
A Merck drug, Lambrolizumab, shrank tumors in 38 percent of advanced melanoma patients, with even better results at the highest doses: a 52 percent tumor shrinkage.
These immunotherapy drugs have shown such promising results early on that some doctors are speculating that patients with melanoma could be cured. Not just in remission — cured.
Nivolumab, the drug in development by Bristol-Myers, is in final-stage trials for patients with lung cancer, kidney tumors, and melanoma. So far, nivolumab has been shown to shrink tumors for between 18 and 28 percent of patients who didn't respond to other treatments.
And for 53 patients given a combination dose of nivolumab and Yervoy, 82 percent were alive after a year, which was a better rate than seen with Yervoy alone.
The race is on for big drug companies to get their hands on a piece of this pie. Right now, at least six other companies are pursuing tests of immune therapy drugs for patients facing advanced cancer.
Much is yet to be discovered, including side effects. Both Bristol-Myers and Merck drug tests showed potential inflammation of the lung as a side effect, among other complications.
Yervoy doubled the number of patients surviving four years after their diagnosis to 19 percent. This success is what brought the idea of immunotherapy to light in conventional care. Now you might say immunotherapy has officially been accepted into mainstream medicine.
A Merck drug, Lambrolizumab, shrank tumors in 38 percent of advanced melanoma patients, with even better results at the highest doses: a 52 percent tumor shrinkage.
These immunotherapy drugs have shown such promising results early on that some doctors are speculating that patients with melanoma could be cured. Not just in remission — cured.
Nivolumab, the drug in development by Bristol-Myers, is in final-stage trials for patients with lung cancer, kidney tumors, and melanoma. So far, nivolumab has been shown to shrink tumors for between 18 and 28 percent of patients who didn't respond to other treatments.
And for 53 patients given a combination dose of nivolumab and Yervoy, 82 percent were alive after a year, which was a better rate than seen with Yervoy alone.
The race is on for big drug companies to get their hands on a piece of this pie. Right now, at least six other companies are pursuing tests of immune therapy drugs for patients facing advanced cancer.
Much is yet to be discovered, including side effects. Both Bristol-Myers and Merck drug tests showed potential inflammation of the lung as a side effect, among other complications.
Let's wait and see
Isn't it nice that mainstream medicine has finally recognized the immune system as a reliable cancer-fighting strategy? And the field is quickly getting crowded. These PD-1-targeting, tumor-shrinking drugs aren't the only approaches to bolstering the immune system that are being studied right now. Amgen Inc. is testing an anti-cancer virus therapy. Because antibodies and viruses target the immune system in different ways, it's believed an anti-cancer virus approach may produce a synergistic effect when combined with other treatments like the ones being developed at Merck and Bristol-Myers.
I think they're on to something. They do, too — Merck senior vice president Gary Gilliland told reporters they have their best people and best teams working on this angle for treatment.
The thing to remember, at the heart of this, is the power of the human immune system. Stimulating it leads to great things. Personally, I'd rather stimulate it naturally, with supplements and dietary approaches that don't prompt dramatic, unknown side effect. Refer to our archives for information on the many ways you can boost your immune system naturally, using proven approaches such as chlorella and spirulina supplements, bovine colostrum, and even good old-fashioned exercise. There's so much material on this subject, it's hard to know where to begin, but I suggest you check out Issue #5, Issue #139, Issue #177, Issue #208 and Issue #220.
I think they're on to something. They do, too — Merck senior vice president Gary Gilliland told reporters they have their best people and best teams working on this angle for treatment.
The thing to remember, at the heart of this, is the power of the human immune system. Stimulating it leads to great things. Personally, I'd rather stimulate it naturally, with supplements and dietary approaches that don't prompt dramatic, unknown side effect. Refer to our archives for information on the many ways you can boost your immune system naturally, using proven approaches such as chlorella and spirulina supplements, bovine colostrum, and even good old-fashioned exercise. There's so much material on this subject, it's hard to know where to begin, but I suggest you check out Issue #5, Issue #139, Issue #177, Issue #208 and Issue #220.
Saturday, June 22, 2013
The Secret of People Who Don't Get Cancer
From the desk of Lee Euler, Editor and Publisher
The secret to curing cancer:
You've been throwing it in the trash!
In 1921, a British doctor discovered that a remote tribal people was almost totally cancer-free. But when members of this tribe move away from their native land and change their diet, they get cancer just like anyone else.
It's all thanks to a food most of us throw away as waste!
One cancer expert calls this overlooked food "the key to curing AND preventing cancer"—and you can benefit NOW -- without going to a doctor or buying expensive supplements.
This little throwaway food tastes great. Bill Clinton (of all people) eats it regularly, and so can you.
|
Cancer -- Step Outside the Box